Observations on oral Sultamicillin/Unasyn CP-45 899 therapy of neonatal infections

Airede, A'k.I.; Jalo, Ilya; Weerasinghe, H. D.; Bello, Mustapha; Adeyemi, S. Debo

doi:10.1016/s0924-8579(96)00359-7

Cited by 7 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sultamicillin (50 mg/kg/day) is also clinically useful and well tolerated in neonates with pneumonia [94].…”

Section: Respiratory Tract Infectionsmentioning

confidence: 99%

“…facial cellulitis of dental origin, retropharyngeal abscess), with equivalent efficacy to comparators such as amoxicillin/clavulanic acid, clindamycin plus cefuroxime, or ceftriaxone or cefuroxime alone (Table 7). In addition, a 92% cure rate was reported in newborn babies with suspected or confirmed SSTIs who were treated with sultamicillin (50 mg/kg/day) [94].…”

Section: Skin and Soft-tissue Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Rational antibiotic therapy and the position of ampicillin/sulbactam

Lode

2008

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Sultamicillin (50 mg/kg/day) is also clinically useful and well tolerated in neonates with pneumonia [94].…”

Section: Respiratory Tract Infectionsmentioning

confidence: 99%

Section: Skin and Soft-tissue Infectionsmentioning

confidence: 99%

Rational antibiotic therapy and the position of ampicillin/sulbactam

Lode

2008

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Effective antimicrobial therapy remains a problem in neonates, and current treatment usually consists of empiric combinations of parenteral antibiotics. 31 Treatment is complicated by the fact that neonates have more extracellular fluid than adults (40% compared with 20% of body mass), which means that comparatively higher doses of antibiotics usually have to be administered. Of the beta-lactam/beta-lactamase combinations currently available, only ampicillin/ sulbactam has received widespread approval for use in neonatal infections; piperacillin/ tazobactam is not licensed for use in neonates in some countries.…”

Section: Adam Beta-lactam/beta-lactamase Inhibitor Combinations In Pediatric Infectionsmentioning

confidence: 99%

Beta-Lactam/Beta-Lactamase Inhibitor Combinations in Empiric Management of Pediatric Infections

Adam

2002

J Int Med Res

View full text Add to dashboard Cite

Beta-lactam antibiotics have long played a central role in the management of pediatric infections. However, widespread beta-lactam resistance among community- and hospital-acquired pathogens, mainly due to beta-lactamase production, has reduced the usefulness of these trusted and well-tolerated agents. Many regions have reported an increase in beta-lactamase-mediated resistance to cephalosporins and carbapenems as well as penicillins among clinically important Gram-positive and Gram-negative aerobes and anaerobes. For some pathogens such as Moraxella catarrhalis, Klebsiella species and Pseudomonas aeruginosa, virtually all strains worldwide are beta-lactamase producers. The development of beta-lactamase inhibitors for co-administration with a number of established beta-lactam agents has restored their usefulness in pediatric patients. The combination of ampicillin plus sulbactam has broad anti-aerobic and anti-anaerobic activity in vitro and achieves high concentrations in many body tissues and fluids. The availability of a mutual oral prodrug, sultamicillin, has enabled the development of an oral formulation. Excellent clinical response and bacterial eradication rates with ampicillin/sulbactam and sultamicillin have been demonstrated for upper and lower respiratory tract infections, urinary tract infections, osteomyelitis, and meningitis in pediatric patients and neonates. Furthermore, many studies have demonstrated an excellent tolerability profile. Thus, ampicillin/sulbactam has an important role in the management of pediatric infections.

show abstract

“…Here it is important to mention that there are some pharmacological tools for the treatment of bacterial diseases [5,6]; unfortunately, since several years ago, bacterial resistance has increased, this phenomenon may be due to some factors, such as; 1) a prolonged antibiotic therapy; 2) uncontrolled antibacterial therapy; or 3) some bacteria have developed several molecular mechanisms as a defense against antibiotics [7]. In the search of new pharmacological tools for treatment of bacterial resistance, have been synthesized some antibacterial drugs to penicillinases inhibition; for example, the preparation of the CP-45,899-drug as an inhibitor of both penicillinases and cephalosporinases bacteria [8]. Additionally, a report showed the preparation of dihidroxifenil-propenona with antibacterial activity against βlactamase of Enterobacter cloacae [9].…”

Section: Introductionmentioning

confidence: 99%

Experimental and theoretical evaluation of two indol-steroid-cyclobuta-imidazole derivatives as antibacterial drugs

2019

Biointerface Res Appl Chem

View full text Add to dashboard Cite

There some for treatment of infectios deseasses; however, some drugs can induce several adverse effects. The aim of this study was synthesizing and to determinate the antibacterial activity of two indol-steroid-cyclobuta-imidazole complex (compound 11 and 12) against Staphylococcus aureus, Escherichia colli and Klebsiella pneumoniae in a minimum inhibitory concentration (MIC) model, using gentamicin, ciprofloxacin, cefotaxime as controls. The following stage involved the theoretical evaluation of the interaction of both compounds 11 and 12 with the β-lactamase enzyme (5f1g) using a docking software. The data found indicate that compound 12 decrease the growth bacterial of Staphylococcus aureus, Escherichia colli and Streptococcus pneumoniae in comparison with the compound 11 and this effect only was similar to cefotaxime Other theoretical data indicated that compound 12 could interact with different type of amino acids residues such as Ser61, Leu116, Gln117, Asp120, Tyr147, Asn149, Ser209, Tyr218, Thr318, Asn342 involved in the surface of 5f1g compared with 11. These data indicate that; i) the steroid derivative (12) show better affinity by the 5f1g protein in comparison with compound 11 which is translated as higher antibacterial activity; ii) this compound is particularly interesting because could constitute a novel therapy as antibacterial agent.

show abstract

Observations on oral Sultamicillin/Unasyn CP-45 899 therapy of neonatal infections

Cited by 7 publications

References 13 publications

Rational antibiotic therapy and the position of ampicillin/sulbactam

Rational antibiotic therapy and the position of ampicillin/sulbactam

Beta-Lactam/Beta-Lactamase Inhibitor Combinations in Empiric Management of Pediatric Infections

Experimental and theoretical evaluation of two indol-steroid-cyclobuta-imidazole derivatives as antibacterial drugs

Contact Info

Product

Resources

About